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Objective/Purpose: The aryl hydrocarbon receptor (AHR) pathway plays a critical role in
the biology of Growth Hormone (GH)-secreting pituitary tumor (somatotropinoma).
Germline rs2066853 AHR variant was found to be more frequent among acromegaly
patients and associated with a more severe disease with larger invasive somatropinoma,
and with resistance to somatostatin analogs treatment in patients living in polluted areas.
However, no somatic changes in AHR gene have been reported so far in acromegaly
patients. On that basis, the aim of the study was to assess at the somatic level the AHR
gene status encompassing exon 10 region, also because of the high rate of variants found
in this genomic region.
Methods: A cohort of 13 patients aged 20–76 years with biochemical, clinical and
histological diagnosis of somatotropinoma was studied. DNA and RNA from pituitary
tumor histological samples have been extracted and analyzed by PCR and direct
sequencing for AHR gene variants, and compared with corresponding patients’
germline DNA as well as normal pituitary tissue as reference control.
Results: A degenerated letter codes in the region corresponding to AHR exon 10
(c.1239-c.2056) was detected in somatotropinomas-derived DNA but not in that of
matched germline and pituitary normal tissue. By multiple PCR and sequencing analysis,
we observed amplification only before codon 1246 and after codon 1254, confirming the
presence of a tumor-restricted somatic deletion in the 5’ upstream region of AHR exon 10.
Analysis of PCR-amplified cDNA revealed a wildtype sequence of exon 9 and 10 in normal
pituitary tissue, and a wildtype sequence of exon 9 and 10 up to codon 1246 and no
sequence after the deletion region (c.1246-c.1254) in 6 out of 9 tumor samples. Patients
carrying the germline rs2066853 AHR variant showed no somatic LOH at the
corresponding genetic locus.n.org November 2020 | Volume 11 | Article 5910391
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Frontiers in Endocrinology | www.frontiersiConclusion: This is the first demonstration of a recurrent somatic deletion in the exon 10
of the AHR gene in somatotropinomas. The functional impact of this genetic finding needs
to be clarified.Keywords: pituitary adenoma, acromegaly, aryl hydrocarbon receptor, somatic deletion, sequencing analysisINTRODUCTION
Amongpituitary tumors, the growthhormone (GH)-secreting ones
(somatotropinomas) account for about 15%–20% of cases, causing
gigantism in children/adolescents while in adults leads to the
clinical picture of acromegaly characterized by overgrowth of
bone and cartilages, and cardiovascular, metabolic, respiratory
and neoplastic complications (1–3). Somatotropinoma
tumorigenesis and pathophysiology is only partially understood,
although several efforts have been made to identify underlying
genetic and epigenetic abnormalities (4). In terms of genetic
background, the most frequently somatic pathogenic events in
somatotropinomas (around 35% of cases) are gain-of-function
mutations in the stimulatory guanine nucleotide (GTP) binding
protein alpha (Gas) encoded by the GNAS gene, with consequent
constitutive cAMP pathway activation (3, 5). On the other hand,
next generation sequencing approach has revealed few relevant
somatic alterations in these tumors such as USP8, GNAS, USP48,
and BRAF (5). In this context, it is worth mentioning that the aryl
hydrocarbon receptor (AHR)-interacting protein (AIP) has been
proven critical in somatotropinoma physiopathology and clinical
expression (6, 7). Indeed, germline inactivating AIP mutations can
predispose to GH-secreting pituitary tumor formation and
associate with a more aggressive clinical phenotype (6). AHR, an
orphan receptor involved in xenobiotics detoxification and inmany
other biological activities, is the intracellular AIP key partner.
Structurally, AHR is composed of several active domains: a N-
terminal bHLH domain responsible for DNA binding, twomedian
PAS domains that serve as ligand binding region, and a glutamine-
rich transcriptional activation domain (TAD) located at the C-
terminal (8, 9). TAD is responsible for protein-protein interactions
with co-regulators and transcription factors (10, 11). In addition, in
this domain reside most of the known polymorphisms. AHR
appears to act as tumor suppressor in GH-secreting pituitary
adenomas (PA) (12). Our research group recently showed that, in
patients with acromegaly living in highly polluted areas, germline
AHR rs2066853 variant, associate with a more severe clinical and
biochemical phenotype, with larger and more invasive
somatotropinomas and resistance to somatostatin analogs
treatment (13–15). These data are in line with the in vitro
findings suggesting that a dysfunctional AHR and/or endocrine
disruptors exposure might affect pituitary tumor biology (7, 12, 16,
17). Nevertheless, despite clear evidence of a potential role of AHR
in somatotropinomas pathophysiology and clinical relevance,
somatic AHR gene alterations in acromegaly patients have not
been reported.
These observations prompted us to assess theAHR gene status at
somatic level in somatotropinomas, including the potential loss of
heterozygosity at the locus of the rs2066853 variant.n.org 2MATERIALS AND METHODS
Human Pituitary Adenoma Tissue
Specimens
The study cohort consisted of 13 patients (8 women and 5 men)
aged 20–76 years with biochemical, clinical and histopathological
diagnosis of GH-secreting pituitary adenoma, referred to the
Endocrine Unit of the University Hospital of Messina. Six
sections from formalin-fixed paraffin-embedded (FFPE) of
each patient and relative germline DNA were obtained.
Postoperative acromegaly remission was observed in eight
patients while the remaining five showed disease persistence or
recurrence. Germline AHR gene status was known for all of
them: five harboured the AHR rs2066853 variant. Other clinical
characteristics of the patient cohort are in Table 1.
The study was approved by the Ethical Committee of the
University Hospital of Messina (Protocol n. 111/16, as of 8/11/
2016) and performed in accordance with the ethical standards
stated in the Declaration of Helsinki. Patients approved the
experimental approach and signed the consensus form prior to
be enrolled in the study.
Genomic DNA Extraction and Sequencing
A pathologist reviewed the haematoxylin and eosin slides
staining to identify tumor vs normal tissue and tumor areas
were subsequently dissected from an unstained FFPE section by
manual microdissection. Genomic DNA was extracted using the
QIAamp DNA FFPE Tissue Kit (QIAGEN) according to the
manufacturer protocol. Five 10-mm thick FFPE sections were
used for each patient. Germline DNA was extracted from fresh
blood samples as described in Cannavò S. et al. (14). All samples
were normalized to the same DNA concentration.
PolymeraseChainReaction (PCR) amplificationwasperformed
in a total volume of 20 ml, containing 10 ml of PCR Master Mix 2X
(ProMEGACorporation) and 1 ml of each primer at concentration
of 10 pmol/ml. The reaction was carried in a Thermocycler PCR
System 9700 (MWG) with an initial denaturation step at 95°C for
3min and then 36 cycles at 95°C for 45 s, 55–60°C for 45 s, 72°C for
45 s, followed by 5 min of final extension at 72°C. PCR primers as
described inCannavòet al. (13) (exon2,5, and10)ordesignedusing
Genamics Expression DNA Sequence Analysis Software and the in
Silico-PCR tool provided by the UCSC Genome Browser (http://
rohsdb.cmb.usc.edu/GBshape/cgi-bin/hgPcr). PCR products were
purified using ExoSTAR 1 Step (EuroClone), directly sequenced on
both strands using BigDyeTerminator V3.1 and subsequently
resolved on an ABI3130 Genetic Analyzer (Applied Biosystems,
Foster City, USA).NM_001621.5was used as reference sequence of
AHR gene. Identified variations were confirmed in a new PCR and
sequencing reaction.November 2020 | Volume 11 | Article 591039
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#A: chr7:17338740+17339068 (329bp) Intron 9-10Fw 5’- GTAG
GGATGTAACCTGACC-3’ and Exon 10_83bp 5’- CATAC
AACACAGCTTCTCCAGTG-3’
#B: chr7:17339084+17339404 (321bp) Exon 10_98bpFw 5’- TTC
CTGCCATAATGGATCCC-3’ and Exon 10_Rev 5’- GACC
TCCAGCAAATGAGTT-3’
#C: chr7:17339322+17339650 (329bp) Exon 10_336bpFw 5’-
TACTGCACCGATGGGAAATG-3’ and Exon 10_10-
666bp_Rev 5’- AGTTCAGAGCCAAGGACTG-3’
#D: chr7:17339632+17339880 (249bp) Exon 10_C Fw 5’- CAGT
CCTTGGCTCTGAACT-3’ and Exon 10_B Rev 5’- GAACT
CTTGACTGATCCCAT-3’
chr7:17338986+17339118 (133bp) Exon 10_Del Fw 5’ AGAT
GAGGAAGGAACAGAGCATT-3’ and Del_Rev 5’- AGTCC
TTAGTGGTAAGGGATCCA-3’RNA Extraction and Sequencing
Total RNA from tumor tissue section identified by pathologist was
extracted and purified using a Qiagen’s RNeasy FFPE Kit. The
quantity and quality of the RNAwere checked byNanodrop (E260,
E260/E280 ratio, spectrum 220–320 nm). cDNA was produced
according to standard protocols. cDNA genotyping was
performed using internal primers for exon 9-10 (Exon 9Fw: 5’-
GACTGGAGAAAGTGGCATGATAGTT-3’; Exon 10Rev pre-
deletion: 5’- CATACAACACAGCTTCTCCAGTG-3’ or Exon
10Rev post-deletion 5’- GACCTCCAGCAAATGAGTT -3’). PCR
reaction and sequencing analysis were performed as for
genomic DNA.
In Silico Analysis
Sequence data obtained from the analysis of exon 10 of the AHR
gene were inspected using Sanger Sequencing and Fragment
Analysis Software SeqScape of Applied Biosystems (ThermoFisher
Scientific). The reference mRNA sequence is NM_001621.5 and
variants are indicated starting from the first nucleotide of the coding
sequence (+1). The reference protein sequence is NP_001612.1. TheFrontiers in Endocrinology | www.frontiersin.org 3variants within the sequence of exon 10 of the AHR gene
(c.1661G>A chr7:g.17339486G>A (hg38) p.Arg554Lys;
c.1246_1254del chr7:g.17339071 (hg38) p.416/417/418) were
searched in gene-specific databases, such as Ensembl Genome
Browser (www.ensembl.org), the Leiden Open Variation database
- LOVD (https://databases.lovd.nl/shared/genes/AHR) and the
NCBI ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar). In
addition, we searched the general population databases, namely the
NCBI Database of Short Genetic Variation – dbSNP (https://www.
ncbi.nlm.nih.gov/snp) and the Genome Aggregation Database -
GnomAD (https://gnomad.broadinstitute.org/). Analysis of these
variants has been performed also with specific database for somatic
mutations such as COSMIC and the Catalogue Of Somatic
Mutations In Cancer.RESULTS
Characterization of Somatic AHR Gene
Variants in GH-Secreting Pituitary Tumors
Both germline and somatic DNA was first analyzed by PCR using
primers validated for sequencing analysis of germline DNA
(gDNA) (chr7:17339632+17340337, c.1239-c.2056) to analyze
exon 10 of AHR gene. Surprisingly, as shown in Figure 1A, no
PCR products of AHR exon 10 (c.1239-c.2056) was detected in
tumor samples compared to pituitary normal tissue, used as
reference control. PCR amplification of other exons of AHR (2
and 5, chr7:17349286+17349945 and chr7:17369421+17369815,
respectively) and a downstream 5’ region of exon 10
(chr7:17379256+17379961, c.1808-intron 10-11) was detected
in tumor tissue and germline DNAs, suggesting the presence of
a putative variant in the upstream exonic region 10 (Figure 1B).
As expected, sequence analysis showed a degenerated letter codes
in tumor DNA (Figure 1C, right panel, and Figure S1) as
compared to DNA from blood of the same patients (Figure
1C, left panel, and Figure S2) and healthy pituitary tissue
(Figure 1C, lower panel, and Figure S3), suggesting a putative






















#1 M 63 43 3b 3,03 4,6 No somatotroph 10 15 Yes No
#2 M 23 20 1 21,8 4,12 Yes somatotroph 4 1 No No
#3 F 20 18 2 20,9 2,3 Yes somatotroph 5 2 Yes No
#4 F 76 15 2 10,9 6,9 No somatotroph 1 0 Yes No
#5 M 57 11 1 2 4,14 Yes somatotroph <1 0 Yes No
#6 M 67 13 1 0,6 1,3 Yes somatotroph 2 N/A No No
#7 F 29 18 1 28 1,61 No somatotroph N/A N/A No No
#8 M 57 22,5 2 12 3,35 No somatotroph 1 0 No No
#9 F 36 15 1 7 1,97 Yes somatotroph N/A N/A No No
#10 F 56 25 2 19 2,44 No somatotroph N/A N/A No No
#11 F 44 16 1 6,7 11 No somatotroph N/A N/A Yes No
#12 F 38 25 3a 31,8 2,9 No somatotroph N/A N/A No No
#13 F 35 15 1 64 1,9 No somatotroph <1 0 No NoNovember 2020 | Volume 11 | AN/A, not available; a, at diagnosis.rticle 591039
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FIGURE 1 | Characterization of somatic aryl hydrocarbon receptor (AHR) mutation in Growth Hormone (GH)-secreting pituitary tumors. (A) Image of a DNA 1%
agarose gel. The leftmost lane contains DNA ladder (1kb plus). Lane 2 shows 817 base pair amplified PCR product of AHR exon 10 (chr7:17339064+17339880;
c.1239-c.2056) of healthy human pituitary sample use as positive control (PC). The subsequent lanes contain a PCR reaction of DNA extract from tumor tissue of
patient with (lanes 3- 7) or without (lanes 8-15) germline polymorphism rs2066853 show lack of detectable amplification of AHR exon 10. Lane 16 shows negative
control (NTC; Non-template control). (B) Image of a DNA 1% agarose gel of representative PCR of germline and tumor DNA for AHR exons 2 (chr7:17309662
+17310321), five (chr7:17329797+17330191) and 10 downstream region (chr7:17339632+17340337; (c.1808-intron 10-11). The leftmost lane contains DNA ladder
(1kb plus). Lanes 2, 9 and 16 show PCR product of germline DNA (gDNA) as reference control. Lanes 3-7, 10-14 and 17-21 shown PCR product of tumor DNA of
patient #3, #5, #2, #8 and #1. Lanes 8, 15 and 22 show negative control without DNA template (NTC; Non-template control). (C) Representative sequence analysis
of AHR exon 10. Electropherograms show the sequence of codon site c. 1310-c.1358 in germline (left panel) and tumor tissue DNA from the patient #1 (right panel),
and healthy pituitary sample (lower panel), use as positive control (PC).Frontiers in Endocrinology | www.frontiersin.org November 2020 | Volume 11 | Article 5910394
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amplification is restricted to the 5’ upstream region of AHR exon
10 and present exclusively in tumor tissue.
Validation of AHR Somatic Deletion
To corroborate the presence of a potential deletion associated with
this region we performed a series of PCR using pairs of primers
designed before and after known insertion and/or deletion variants
throughout exon 10 of the AHR gene. The primers design was
according with the SNP database (Short Genetic Variation;/www.
ncbi.nlm.nih.gov) as germline pathogenic mutations: rs764425858
( in- f rame de l e t ion HGVS Name : c .1246_1254de l ;
p.Ala416_Asn418del; Position g.17339071_17339079del)
rs760349720 (in frame deletion HGVS Name: c.1481_1483del;
p.Arg494del; Position g.17339306_17339308del) and
rs778350893 (in frame deletion HGVS Name: c.1893_1895del;
p.Val632del; Position g.17339718_17339720del). Of note, to date
there are no somatic pathogenic deletions upstream of exon 10
reported in COSMIC database (Catalogue of Somatic Mutations In
Cancer).We screened specific exonic regions: upstream the variant
rs764425858 (PCR#A; intron 9-10 - c.1243); downstream
rs764425858 and upstream rs760349720 (PCR#B; c.1260-c.1579);
downstreamrs760349720and/orbetween thevariants rs760349720
and rs778350893 (PCR#C-D; c.1497-c.1807 and c.1807-c.2055). Of
interest, we observed amplification only before codon 1246 and
after codon 1254 (rs764425858), strengthening the evidence of a
somatic deletion in our patients (Figure 2A) in the 5’ upstream
region of exon 10, corresponding to the PCR-binding site of primer
used for mutational analysis (chr7:17339632+17340337, c.1239-
c.2056) (13). Sequencing data of these samples were then screened
to validate the presence of the in frame deletion rs764425858 at
somatic level. Results revealed an altered sequence of AHR at this
level compared to germline DNA (Figure S4).
Of interest, we were able to extract RNA from FFPE tumor
specimens of nine of our patients and performed mutational
analyses on cDNA after amplification of exon 9 and 10 to validate
the effect of this deletion at the mRNA level. Sequencing analysis of
PCR-amplified cDNA (Figure 2B, C andFigure S5, S6) revealed: i.
a correct sequence of exon 9 and 10 up to codon 1246 (Figure 2C
andFigureS6, left panel; amplification region c.1027-c.1243); ii. the
lack of sequence data due to the absence of the priming site after the
deletion region (c.1246-c.1254) (Figure 2C and Figure S6, right
panel; amplification region c.1027-c.1579) in 6 of 9 tumor samples,
compared to pituitary normal tissue, used as reference control
(Figure 2B and Figure S5). The lack of specific amplification of
these genomic regions in theother threepatientsmight bedue to the
low amount of RNA obtained.
The above observation is consistent with the hypothesis that
GH-secreting pituitary adenoma carries this variant, and that
this somatic mutation is likely to be inactivating and therefore
potentially affecting pituitary tumor pathophysiology.
Evaluation of Loss of Heterozygosity
It is known that the germline SNP rs2066853 may have an
impact on AHR gene structure/function and that this
polymorphism is more frequent among acromegaly patients
and associated with a worse clinical outcome, biochemicalFrontiers in Endocrinology | www.frontiersin.org 5profile and more invasive pituitary tumor. Given the evidence
that this SNP is more frequent in heterozygosis and the
phenomenon of loss of heterozygosity (LOH) is associated
with tumor progression, we assumed that this variant and its
LOH might be involved in pituitary tumor pathogenesis.
To investigate a potential LOHwe performed direct sequencing
analysis of the genetic locus of AHR in tumor DNA of patients
carrying or not this germline variant. We therefore amplified the
downstream region of exon 10 including SNP rs2066853 using
primers designed after the site of in frame deletion rs764425858
(codon 1254). Data revealed the absence of loss of heterozygosis of
this missense variant (Genomic Mutation ID: COSV54123264) in
patients carrying the variant rs2066853 at germline context (Figure
3 and Figures S7-10).DISCUSSION
AHR is a ligand-activated transcription factor that can bind over
400 different endogenous and exogenous compounds, including
several endocrine disrupting chemicals and environmental
contaminants (17–19). AHR activation leads to the transactivation
of genes encoding phase I and II xenobiotics metabolizing enzymes,
thus representing a key factor of the intracellular detoxification
systems (20). The AHR has been therefore studied mainly in the
context of environmental pollutants processing as transcriptional
regulator of genes involved in the metabolism and/or excretion of
toxins such as dioxin TCDD (21). Moreover, AHR is directly or
indirectly involved in many other biologically relevant processes -
via the so-called non-canonical pathways – such as cell cycle
regulation and cell contact inhibition, potentially contributing to
tumorigenesis (22–24). A limited number of studies has focused on
the impact of AHR signaling in PA. Jaffrain-Rea in 2009 reported
that the AHR and its partner AIP were downregulated in aggressive
somatotropinomas as compared to non-invasive adenomas
suggesting their involvement in the acquisition of an aggressive
phenotype (25). Subsequently, several groups focused their attention
on the uncovered link between AHR and/or AIP expression and the
molecular mechanisms underlying pituitary adenoma pathogenesis.
AIP, a co-chaperone protein that acts as a tumor suppressor in
pituitary cells (26), is critical for AHR stabilization and function.
AIP gene germline mutations have been found in young patients
with familial or apparently sporadic aggressive pituitary adenomas,
mostly secreting GH and/or PRL, and less responsive to
conventional medical treatments (27). Moreover, although it is
still a matter of debate, AIP mutations also affect the AHR
signaling, since they can alter the AHR and phosphodiesterase
(PDE)4A5 interaction and consequently the cAMP pathway,
affecting pituitary function and tumorigenesis (22, 28). Several
AHR gene polymorphisms have been described, mostly in exon
10, with some of them associated with an altered induction of
CYP1A1 and CYP1A2 activity in response to specific ligands (29).
Our group showed that the germline single nucleotide
polymorphism (SNP) rs2066853 of the AHR encoding gene is
more frequent in acromegaly patients as compared to sex- and age-
matched healthy subjects and is associated with increased pituitary
adenoma invasiveness and secondary neoplasm’s risk (13). OfNovember 2020 | Volume 11 | Article 591039
Re et al. AHR Somatic Deletion in Somatotropinomainterest, in 2016 a study revealed that this SNP, causing an arginine
to lysine substitution in the TAD domain at codon 554 (R554K),
may affect AHR protein structure and function (30). To date only
germline pathogenic variants of AHR andAIP have been described
and, beyond GNAS gene somatic mutations, no obvious driver
somatic alterations have been so far identified in GH-secreting
pituitary adenoma (31, 32). Interestingly, all AHR SNPs described
so far reside in exon 10, encoding the TAD, and are associated with
other neoplasms, including gliomas (13, 14, 33).Frontiers in Endocrinology | www.frontiersin.org 6The present study describes for thefirst time a recurrent somatic
sequence alteration in exon 10 of AHR gene associated with GH-
secreting macroadenoma. Sequence analysis of DNA and RNA
from somatotropinoma histological samples derived from patients
carrying or not the germline rs2066853AHR variant revealed an in
frame deletion on AHR coding sequence c.1246-1254 as compared
topatients’matchedgermlineDNAandpituitarynormal tissue. It is
a somatic deletion exclusively in the tumor tissue. Of interest, this
sequence variant, known as germinal polymorphism rs764425858A
B
C
FIGURE 2 | Validation of in frame somatic deletion on tumor DNA. (A) Schematic image of the human aryl hydrocarbon receptor (AHR) gene structure and
localization of in frame deletion. Double-headed arrow lines identify the regions A–D amplified by PCR; single arrow lines identify primers used to amplify deletion
region. Representative PCR for AHR exon 10 regions of tumor DNA of patient #5. The leftmost lane contains DNA ladder (1kb plus). Lane 2 shows PCR product of
exonic region upstream the variant rs764425858 (PCR#A). Lane 3 shows PCR product of exonic region downstream the variant rs764425858 and upstream the
variant rs760349720 (PCR#B). Lane 4 shows PCR product of exonic region downstream variants rs760349720 and rs760349720 and upstream the variant
rs778350893 (PCR#C). Lane 5 shows PCR product of exonic region between the variants rs760349720 and rs778350893 (PCR#D). White lines indicate PCR
products run in non-contiguous lanes of the same gel. (B, C) Representative sequence analysis on cDNA after amplification of AHR exon 9 and 10 in healthy pituitary
sample (B) and tumor samples (patient #5) (C). Left panel shows electropherogram with a focus on the amplified region c.1027-c.1243 (PCR of exon 9 and
upstream exon 10, before deletion site; c.1181-c.1243). Right panel shows electropherogram with a focus on the amplified region c.1224-c.1243 (PCR of exon 9
and upstream exon 10, after deletion site (c.1027-c.1579).November 2020 | Volume 11 | Article 591039
Re et al. AHR Somatic Deletion in Somatotropinoma(GRCh38/hg38, Chr7:17339071-17339079) with a highest minor
allele frequency (MAF) <0.01% (EVA_EXAC, GNOMAD,
Genomes Project phase III and Ensembl) is located within a
regulatory region with structural feature resembling an enhancer
(ENSR00001121919). Specifically, Ensembl and Encode databases
report a specific interaction between RNA polymerase and
transcription factors, such as C-Fos, CREB, and EZH2, capable to
control transcription in a cell type or tissue-dependent manner.
This might imply that this AHR somatic deletion could interfere
with co-regulators and transcription factors potentially impairing
the AHR function. Moreover, the somatic alteration is located
within TAD domain at the C-terminal region of AHR. The lack
of coding sequence in this region might affect protein structure. In
light of these considerations we speculated that in pituitary tumors
of acromegaly patients with or without AHR/AIP germline genetic
variants, this novel somatic deletion of AHR exon 10 (c.1246-1254)
could contribute to alter the AHR pathway and favor tumor
development. The limitations of this study are the relatively small
numberof cases,which ismainlydue to several factors: i) thedisease
is rare; a limited number of donors were available, ii) a single center
has carried out sample collection, iii) tumors in the study are all
somatotropinomas. Besides, frequently surgical samples did not
contain sufficient material to allow efficient yields for ‘pure’
pituitary tumor DNA and RNA extraction and analysis. Because
of the limitations listed above, our study was performed on a
restricted number of samples. Hence, our findings, although
consistent, must be considered purely indicative.Frontiers in Endocrinology | www.frontiersin.org 7In conclusion, this is the first demonstration of a recurrent
somatic deletion in the exon 10 of the AHR gene in GH-secreting
tumors, whose functional impact however needs to be clarified.DATA AVAILABILITY STATEMENT
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